| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment MP Morelli, MJ Overman, A Dasari, SMA Kazmi, T Mazard, E Vilar, ... Annals of Oncology 26 (4), 731-736, 2015 | 279 | 2015 |
| Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors MP Morelli, T Cascone, T Troiani, F De Vita, M Orditura, G Laus, ... Annals of Oncology 16, iv61-iv68, 2005 | 159 | 2005 |
| Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy F Ciardiello, T Troiani, R Bianco, M Orditura, F Morgillo, E Martinelli, ... Annals of Oncology 17, vii109-vii114, 2006 | 141 | 2006 |
| 5-fluorouracil resistant colon cancer cells are addicted to OXPHOS to survive and enhance stem-like traits C Denise, P Paoli, M Calvani, ML Taddei, E Giannoni, S Kopetz, ... Oncotarget 6 (39), 41706, 2015 | 139 | 2015 |
| PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response HW Liao, JM Hsu, W Xia, HL Wang, YN Wang, WC Chang, ST Arold, ... The Journal of clinical investigation 125 (12), 4529-4543, 2015 | 134 | 2015 |
| Telomere length maintenance in aging and carcinogenesis. M Aragona, R Maisano, S Panetta, A Giudice, M Morelli, I La Torre, ... International journal of oncology 17 (5), 981-990, 2000 | 95 | 2000 |
| Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft MP Morelli, E Calvo, E Ordoñez, MJ Wick, BR Viqueira, PP Lopez-Casas, ... Journal of Clinical Oncology 30 (4), e45, 2012 | 94 | 2012 |
| Therapeutic silencing of KRAS using systemically delivered siRNAs CV Pecot, SY Wu, S Bellister, J Filant, R Rupaimoole, T Hisamatsu, ... Molecular cancer therapeutics 13 (12), 2876-2885, 2014 | 92 | 2014 |
| Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer JJ Tentler, S Nallapareddy, AC Tan, A Spreafico, TM Pitts, MP Morelli, ... Molecular cancer therapeutics 9 (12), 3351-3362, 2010 | 91 | 2010 |
| Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells E Martinelli, T Troiani, F Morgillo, G Rodolico, D Vitagliano, MP Morelli, ... Clinical Cancer Research 16 (20), 4990-5001, 2010 | 89 | 2010 |
| Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer C Xie, AG Duffy, D Mabry‐Hrones, B Wood, E Levy, V Krishnasamy, ... Hepatology 69 (5), 2048-2060, 2019 | 85 | 2019 |
| Anti‐tumor activity of the combination of cetuximab, an anti‐EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases MP Morelli, T Cascone, T Troiani, C Tuccillo, R Bianco, N Normanno, ... Journal of cellular physiology 208 (2), 344-353, 2006 | 79 | 2006 |
| Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer VK Morris, FA San Lucas, MJ Overman, C Eng, MP Morelli, ZQ Jiang, ... Annals of Oncology 25 (10), 2008-2014, 2014 | 58 | 2014 |
| Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. VK Morris, CM Parseghian, M Escano, B Johnson, KPS Raghav, A Dasari, ... Journal of Clinical Oncology 40 (4_suppl), 12-12, 2022 | 57 | 2022 |
| MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon K Raghav, V Morris, C Tang, P Morelli, HM Amin, K Chen, GC Manyam, ... Oncotarget 7 (34), 54627, 2016 | 57 | 2016 |
| Association of blood biomarkers and autoimmunity with immune related adverse events in patients with cancer treated with immune checkpoint inhibitors D Michailidou, AR Khaki, MP Morelli, L Diamantopoulos, N Singh, ... Scientific reports 11 (1), 9029, 2021 | 51 | 2021 |
| Targeting vascular endothelial growth factor receptor-1 and-3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines MP Morelli, AM Brown, TM Pitts, JJ Tentler, F Ciardiello, A Ryan, ... Molecular cancer therapeutics 8 (9), 2546-2558, 2009 | 50 | 2009 |
| Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines JL Spratlin, TM Pitts, GN Kulikowski, MP Morelli, JJ Tentler, NJ Serkova, ... Anticancer research 31 (4), 1093-1103, 2011 | 49 | 2011 |
| Modeling of patient-derived xenografts in colorectal cancer A Katsiampoura, K Raghav, ZQ Jiang, DG Menter, A Varkaris, MP Morelli, ... Molecular cancer therapeutics 16 (7), 1435-1442, 2017 | 45 | 2017 |
| Synergistic anti‐proliferative and pro‐apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti‐epidermal growth factor receptor (EGFR) drugs … T Cascone, MP Morelli, F Morgillo, WY Kim, G Rodolico, S Pepe, ... Journal of cellular physiology 216 (3), 698-707, 2008 | 44 | 2008 |
